Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +0.92% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M 100.0% | $67.6M 100.0% | $79.2M 100.0% | $86.2M 100.0% | $97.1M 100.0% | $122.5M 100.0% | $205.2M 100.0% | $206.6M 100.0% | $102.8M 100.0% | $88.3M 100.0% |
| Research & Development | $106.7M 163.4% | $131.5M 194.4% | $163.5M 206.5% | $164.5M 190.9% | $174.1M 179.4% | $136.8M 111.7% | $142.2M 69.3% | $94.9M 45.9% | $57.5M 55.9% | $40.5M 45.8% |
| Selling, General & Admin | $43.9M 67.3% | $57.9M 85.5% | $52.9M 66.8% | $45.5M 52.8% | $32.5M 33.5% | $27.4M 22.3% | $26.2M 12.8% | $23.4M 11.3% | $20.7M 20.2% | $17.0M 19.2% |
| Total Operating Expenses | $150.7M 230.7% | $189.3M 279.9% | $216.4M 273.2% | $210.0M 243.7% | $206.6M 212.9% | $164.1M 134.0% | $168.5M 82.1% | $118.3M 57.3% | $78.2M 76.1% | $57.4M 65.1% |
| Operating Income | -$85.3M -130.7% | -$121.7M -179.9% | -$137.2M -173.2% | -$123.8M -143.7% | -$109.6M -112.9% | -$41.6M -34.0% | $36.7M 17.9% | $88.3M 42.7% | $24.6M 23.9% | $30.8M 34.9% |
| Interest Expense | $7.7M 11.8% | $10.9M 16.2% | $5.1M 6.5% | $0 0.0% | $0 0.0% | — | — | — | $40K 0.0% | $45K 0.1% |
| Interest & Investment Income | — | — | — | — | — | — | — | — | $2.5M 2.5% | $1.7M 2.0% |
| Other Income (Expense), net | $1.8M 2.8% | $3.9M 5.8% | $6.2M 7.8% | $1.7M 1.9% | $2.0M 2.1% | $6.6M 5.4% | $8.8M 4.3% | $4.8M 2.3% | $2.3M 2.3% | $1.7M 1.9% |
| Pretax Income | -$83.5M -127.9% | -$117.8M -174.2% | -$131.0M -165.4% | -$122.2M -141.8% | -$107.6M -110.8% | -$35.0M -28.6% | $45.6M 22.2% | $93.1M 45.1% | $26.9M 26.2% | $32.6M 36.9% |
| Income Tax Expense | -$1.7M -2.5% | -$1.7M -2.6% | $2.8M 3.6% | -$433K -0.5% | -$28.6M -29.4% | $1.1M 0.9% | -$826K -0.4% | $21.2M 10.2% | $9.2M 9.0% | $10.9M 12.3% |
| Net Income | -$81.9M -125.4% | -$116.0M -171.6% | -$133.8M -169.0% | -$121.8M -141.3% | -$79.0M -81.4% | -$36.2M -29.5% | $46.4M 22.6% | $72.0M 34.8% | $17.7M 17.2% | $21.7M 24.5% |
| Per Share | ||||||||||
| EPS (Basic) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2.37 | $3.74 | $0.93 | $1.14 |
| EPS (Diluted) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2.21 | $3.48 | $0.91 | $1.13 |
| Weighted Avg Shares (Basic) | 21K | 21K | 21K | 21K | 20K | 20K | 19.6M | 19.3M | 19.1M | 18.9M |
| Weighted Avg Shares (Diluted) | 21K | 21K | 21K | 21K | 20K | 20K | 21.0M | 20.6M | 19.4M | 19.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$32M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -127%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-08-05
No standout strengths flagged.
Where each multiple sits in its own 13-yr range · 62th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 8.7× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| R&D | 45.9 | 69.3 | 111.7 | 179.4 | 190.9 | 206.5 | 194.4 | 163.4 |
| SG&A | 11.3 | 12.8 | 22.3 | 33.5 | 52.8 | 66.8 | 85.5 | 67.3 |
| Operating Income | 42.7 | 17.9 | -34.0 | -112.9 | -143.7 | -173.2 | -179.9 | -130.7 |
| Income Tax | 10.2 | -0.4 | 0.9 | -29.4 | -0.5 | 3.6 | -2.6 | -2.5 |
| Net Income | 34.8 | 22.6 | -29.5 | -81.4 | -141.3 | -169.0 | -171.6 | -125.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ENTA: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| ENTA | $283M | — | — | 4.3× | -3.4% | — | -125% | -127% | -127% | — | 127 |
Peers = companies sharing ENTA's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.